Abstract
Amyotrophic Lateral Sclerosis, known as ALS, is a neurodegenerative disease that passes the death sentence on 15 new people every day, leaving a patient struggling to move their fingers. At the molecular level, motor neuron death causes the inability for the muscles to function as normal. After researchers studied motor neuron death in ALS patients’ cells, they found that in all diseased cells, the SFPQ protein, a vital nuclear DNA/RNA binding protein, left the nucleus (its original location) and ended up in the cytoplasm. Since this defect was a molecular hallmark of ALS, solving this problem could stop motor neuron death. To treat this molecular hallmark, the in-silico process was used to sift through thousands of potential molecules to find the best one to use. The in-silico method was used to identify a lead molecule (NLS 551) that passed all the in-silico tests and brought the SFPQ protein back into the nucleus. If successful, this identified molecule could serve as the base for an ALS treatment.